Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

El-Khoueiry A.B.Sangro B.Yau T.Crocenzi T.S.Kudo M.CHIUN HSUKim T.-Y.Choo S.-P.Trojan J.Welling T.H.3rd, Meyer T.Meyer T.3rdKang Y.-K.Yeo W.Chopra A.Anderson J.dela Cruz C.Lang L.Neely J.Tang H.Dastani H.B.Melero I.2022-08-192022-08-1920170140-6736https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018660134&doi=10.1016%2fS0140-6736%2817%2931046-2&partnerID=40&md5=e2e26b2258101debb72474536abee580https://scholars.lib.ntu.edu.tw/handle/123456789/617130Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialjournal article10.1016/S0140-6736(17)31046-2284346482-s2.0-85018660134